Patents by Inventor Steven Moss

Steven Moss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240109845
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Application
    Filed: March 31, 2023
    Publication date: April 4, 2024
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS
    Publication number: 20240033320
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of activating GnRH receptors when administered to animal or human patients or cells. These immunorhelins have utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Application
    Filed: December 14, 2022
    Publication date: February 1, 2024
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL COMPOUNDS (IMMUNORHELINS)
    Publication number: 20230118205
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
    Type: Application
    Filed: August 16, 2022
    Publication date: April 20, 2023
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Immunorhelin compounds for intracellular infections
    Patent number: 11564969
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of activating GnRH receptors when administered to animal or human patients or cells. These immunorhelins have utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: January 31, 2023
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (publ)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Compounds (immunorhelins)
    Patent number: 11434258
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 6, 2022
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Use of known compounds—intracellular infections
    Patent number: 11304990
    Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 19, 2022
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS
    Publication number: 20210401792
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Cell-permeable succinate compounds
    Patent number: 11147789
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: October 19, 2021
    Assignee: ABLIVA AB
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Compositions and methods for treating cancer
    Patent number: 11136297
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of California
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • Immune stimulating macrolides
    Patent number: 11059845
    Abstract: The present invention provides immune stimulating macrolides of formula (I), wherein the substituents are as defined in claim 1. The macrolides have utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 13, 2021
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Immune stimulating compound
    Patent number: 11059846
    Abstract: The present invention provides immune stimulating macrolide of formula (I). The macrolide has utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 13, 2021
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Immune stimulating macrolides
    Patent number: 11059844
    Abstract: The present invention provides immune stimulating macrolides of formula (I), wherein the substituents are as defined in the claims. The macrolides have utility in treating viral diseases and cancer.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 13, 2021
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • Immune stimulating macrolide
    Patent number: 10919927
    Abstract: The present invention provides immune stimulating macrolide of formula (I). The macrolide has utility in treating viral diseases and cancer.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 16, 2021
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Robert Wallin, Emma Lindh, Matt Gregory, Steven Moss
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20200131135
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 30, 2020
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • NOVEL IMMUNE STIMULATING MACROLIDES
    Publication number: 20200010498
    Abstract: The present invention provides immune stimulating macrolides of formula (I), wherein the substituents are as defined in the claims. The macrolides have utility in treating viral diseases and cancer.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 9, 2020
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL IMMUNE STIMULATING COMPOUND
    Publication number: 20200010499
    Abstract: The present invention provides immune stimulating macrolide of formula (I). The macrolide has utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 9, 2020
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL IMMUNE STIMULATING MACROLIDES
    Publication number: 20190389896
    Abstract: The present invention provides immune stimulating macrolides of formula (I), wherein the substituents are as defined in claim 1. The macrolides have utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Application
    Filed: February 22, 2018
    Publication date: December 26, 2019
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL COMPOUNDS (IMMUNORHELINS)
    Publication number: 20190389908
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 26, 2019
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL COMPOUNDS (IMMUNORHELINS - INTRACELLULAR INFECTIONS)
    Publication number: 20190388497
    Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of activating GnRH receptors when administered to animal or human patients or cells. These immunorhelins have utility in treating intracellular bacterial, fungal, and protozoal infections.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 26, 2019
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
  • NOVEL USE OF KNOWN COMPOUNDS - INTRACELLULAR INFECTIONS
    Publication number: 20190374598
    Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 12, 2019
    Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss